Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateMaxCyte, Inc. Common Stock
XNAS•Health Care•Services-Commercial Physical & Biological Research
Flagged at $1.06 at 08:06 AM on Oct 14, then ran to $1.33 +25% that session.
The high is the session peak after our first alert, not a realized trade. Not investment advice.
Why is MXCT up today? It is at $1.39 (+0.00%), and our scanner flagged it 67 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment MXCT spikes, and full due diligence on MXCT — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $MXCT 67 times in the last 30 days. Create a free account to track $MXCT, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on MXCT from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for MXCT today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystMaxCyte Reports Preliminary Third Quarter 2026Reported Core business revenue of approximately $8.1 millionReported in the third quarter of 2026, an increase of 26% compared to the third quarter of 2025.Reported Program-related revenue of more than $1.0 million, including milestone revenue of $1.0 million received in the third quarter of 2026., from an SEC filing. Read it →Latest filingSC 13DActivist 5%+ stake disclosedOct 15, 2026 · 10 days agoSources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Al-Wakeel Yasir B. Director | Acquired (grant/award) | +30K 0.03% of company | added 60% | 81K | n/a | Jun 17, 26 |
Balthrop Patrick J Director | Acquired (grant/award) | +30K 0.03% of company | added 60% | 81K | n/a | Jun 17, 26 |
Brooke William W Director | Acquired (grant/award) | +30K 0.03% of company | added 20% | 181K | n/a | Jun 17, 26 |
Collins Cynthia Director | Acquired (grant/award) | +30K 0.03% of company | added 38% | 111K | n/a | Jun 17, 26 |
Douglas Richard Director | Acquired (grant/award) | +30K 0.03% of company | added 13% | 261K | n/a | Jun 17, 26 |
Erck Stanley C Director | Acquired (grant/award) | +30K 0.03% of company | added 7.6% | 429K | n/a | Jun 17, 26 |
Hemrajani Rekha Director | Acquired (grant/award) | +30K 0.03% of company | added 76% | 70K | n/a | Jun 17, 26 |
Johnston John Joseph Director | Acquired (grant/award) | +30K 0.03% of company | added 18% | 202K | n/a | Jun 17, 26 |
Ahuja Parmeet Officer | Acquired (grant/award) | +188K 0.2% of company | n/a | 188K | n/a | Apr 15, 26 |
Masoud Maher Officer | Acquired (grant/award) | +300K 0.3% of company | added 100% | 475K | n/a | Mar 27, 26 |
Swirsky Douglas J Officer | Sold (automatic/other) | -10K | sold 6.3% | 152K | $8K at $0.810 | Mar 17, 26 |
Brooke William W Director | Bought (open market) | +50K 0.05% of company | added 50% | 151K | $65K at $1.29 | Aug 13, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in services-commercial physical & biological research, closest in size first.
Here is the latest on MXCT from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for MXCT today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
MXCT last traded at $1.39, up 0.00% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
MaxCyte, Inc. Common Stock (MXCT) is next expected to report earnings on Tuesday, November 10, 2026 (after close), about 16 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The MXCT Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged MXCT 67 times in the last 30 days.
MXCT (MaxCyte, Inc. Common Stock) trades on XNAS, with a market cap of about $144M in the Services-Commercial Physical & Biological Research sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge MXCT for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$MXCT discussion
Sign in to ask a question or join the discussion.